Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0H1OL
|
||||
| Former ID |
DNC002557
|
||||
| Drug Name |
Guanosine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Phase 1 | [1], [2] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H13N5O5
|
||||
| InChI |
InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1
|
||||
| InChIKey |
NYHBQMYGNKIUIF-UUOKFMHZSA-N
|
||||
| CAS Number |
CAS 118-00-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
2780, 3677, 585265, 650442, 822708, 828520, 834086, 838453, 841595, 3133368, 7887938, 8026827, 8144918, 8154424, 10318628, 12075474, 14775401, 15914598, 16572157, 24715024, 25622152, 26512273, 26683878, 26710719, 26737546, 26754281, 29225747, 46392771, 46394142, 49830512, 49974991, 56413296, 57288125, 57323721, 74382935, 76715720, 77560081, 81044586, 81059141, 85164932, 85279369, 87570365, 88835475, 89649885, 90451714, 103510778, 103825631, 104313108, 117358482, 117529640
|
||||
| Target and Pathway | |||||
| Target(s) | DNA polymerase | Target Info | Inhibitor | [3] | |
| HCMV DNA polymerase | Target Info | Inhibitor | [3] | ||
| DNA polymerase (HSV-2) | Target Info | Inhibitor | [3] | ||
| Purine nucleoside phosphorylase | Target Info | Inhibitor | [3] | ||
| BioCyc Pathway | Arsenate detoxification I (glutaredoxin) | ||||
| Purine nucleotides degradation | |||||
| Urate biosynthesis/inosine 5'-phosphate degradation | |||||
| Purine deoxyribonucleosides degradation | |||||
| Purine ribonucleosides degradation to ribose-1-phosphate | |||||
| Guanosine nucleotides degradation | |||||
| Adenosine nucleotides degradation | |||||
| Superpathway of purine nucleotide salvage | |||||
| Adenine and adenosine salvage III | |||||
| Guanine and guanosine salvage | |||||
| KEGG Pathway | Purine metabolism | ||||
| Pyrimidine metabolism | |||||
| Nicotinate and nicotinamide metabolism | |||||
| Metabolic pathways | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | |||||
| PANTHER Pathway | Adenine and hypoxanthine salvage pathway | ||||
| Xanthine and guanine salvage pathway | |||||
| PathWhiz Pathway | Purine Metabolism | ||||
| Nicotinate and Nicotinamide Metabolism | |||||
| Reactome | Purine salvage | ||||
| Purine catabolism | |||||
| WikiPathways | miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in leukocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| Metabolism of nucleotides | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4567). | ||||
| REF 2 | ClinicalTrials.gov (NCT01493570) Assessment of Exposure of BI 409306 in Cerebrospinal Fluid (CSF) Relative to Plasma as Well as to Evaluation of the Effect of Different Doses of BI 409306 on the cGMP(Cyclic Guanosine Monophosphate) Levels in CSF in Healthy Male Volunteers. U.S. National Institutes of Health. | ||||
| REF 3 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.